|
1
|
Ruiz-Rodado V, Seki T, Dowdy T, Lita A, Zhang M, Han S, Yang C, Cherukuri MK, Gilbert MR, Larion M. Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma. Cancers (Basel) 2020; 12:E1633. [PMID: 32575619 PMCID: PMC7352932 DOI: 10.3390/cancers12061633] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 06/11/2020] [Accepted: 06/16/2020] [Indexed: 12/21/2022] Open
Abstract
Understanding the metabolic reprogramming of aggressive brain tumors has potential applications for therapeutics as well as imaging biomarkers. However, little is known about the nutrient requirements of isocitrate dehydrogenase 1 (IDH1) mutant gliomas. The IDH1 mutation involves the acquisition of a neomorphic enzymatic activity which generates D-2-hydroxyglutarate from α-ketoglutarate. In order to gain insight into the metabolism of these malignant brain tumors, we conducted metabolic profiling of the orthotopic tumor and the contralateral regions for the mouse model of IDH1 mutant glioma; as well as to examine the utilization of glucose and glutamine in supplying major metabolic pathways such as glycolysis and tricarboxylic acid (TCA). We also revealed that the main substrate of 2-hydroxyglutarate is glutamine in this model, and how this re-routing impairs its utilization in the TCA. Our 13C tracing analysis, along with hyperpolarized magnetic resonance experiments, revealed an active glycolytic pathway similar in both regions (tumor and contralateral) of the brain. Therefore, we describe the reprogramming of the central carbon metabolism associated with the IDH1 mutation in a genetically engineered mouse model which reflects the tumor biology encountered in glioma patients.
Collapse
Affiliation(s)
- Victor Ruiz-Rodado
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| | - Tomohiro Seki
- Radiation Biology Branch, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (T.S.); (M.K.C.)
| | - Tyrone Dowdy
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| | - Adrian Lita
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| | - Meili Zhang
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| | - Sue Han
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| | - Chunzhang Yang
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| | - Murali K. Cherukuri
- Radiation Biology Branch, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (T.S.); (M.K.C.)
| | - Mark R. Gilbert
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| | - Mioara Larion
- Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institute of Health, Bethesda, MD 20814, USA; (V.R.-R.); (T.D.); (A.L.); (M.Z.); (S.H.); (C.Y.); (M.R.G.)
| |
Collapse
|
|
2
|
Zasada C, Kempa S. Quantitative Analysis of Cancer Metabolism: From pSIRM to MFA. Recent Results Cancer Res 2016; 207:207-20. [PMID: 27557540 DOI: 10.1007/978-3-319-42118-6_9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Metabolic reprogramming is a required step during oncogenesis and essential for cellular proliferation. It is triggered by activation of oncogenes and loss of tumor suppressor genes. Beside the combinatorial events leading to cancer, common changes within the central metabolism are reported. Increase of glycolysis and subsequent lactic acid formation has been a focus of cancer metabolism research for almost a century. With the improvements of bioanalytical techniques within the last decades, a more detailed analysis of metabolism is possible and recent studies demonstrate a wide range of metabolic rearrangements in various cancer types. However, a systematic and mechanistic understanding is missing thus far. Therefore, analytical and computational tools have to be developed allowing for a dynamic and quantitative analysis of cancer metabolism. In this chapter, we outline the application of pulsed stable isotope resolved metabolomics (pSIRM) and describe the interface toward computational analysis of metabolism.
Collapse
Affiliation(s)
- Christin Zasada
- Integrative Proteomics and Metabolomics, Max-Delbrueck-Center of Molecular Medicine in the Helmholtz Association, Robert-Roessle-Str. 10, 13125, Berlin, Germany
| | - Stefan Kempa
- Integrative Proteomics and Metabolomics, Max-Delbrueck-Center of Molecular Medicine in the Helmholtz Association, Robert-Roessle-Str. 10, 13125, Berlin, Germany.
| |
Collapse
|